Gamma knife stereotactic radiosurgery for acromegaly
Related Experiment Video
Updated: Jul 12, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Einar Osland Vik-Mo1, Marianne Oksnes, Paal-Henning Pedersen
1Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway. e.o.vik-mo@medisin.uio.no
Background:
Gamma knife radiosurgery (GKR) is an adjuvant treatment for acromegaly if surgery fails to normalize GH hypersecretion.
Objective:
To examine the effect of GKR on tumor growth and hypersecretion, and to characterize the adverse effect of this treatment.
Design:
Cross-sectional follow-up study. First, retrospective data pre- and post-GKR were collected. PATIENTS then underwent a predefined survey including radiological, endocrinological, ophthalmological, and neurosurgical evaluation.
Setting:
Norwegian National Center for gamma knife treatment.
Patients:
Sixty-one patients treated with GKR for acromegaly. Out of 55, 53 living patients underwent a detailed survey. The mean follow-up was 5.5 years. No patient was lost to follow-up.
Results:
Tumor growth was stopped in all patients. At 3, 5, and 10 years after GKR, 45, 58, and 86% of patients had normal IGF-I levels. Consecutive hormone value analysis showed that patients receiving GH-suppressive medication had a more rapid decline in hypersecretion than those who did not receive such medication. Evaluated by survey baseline values alone, non-elevated IGF-I and GH levels below 5 mIU/l were found in 38%. GH-suppressive medication was terminated in 16 out of 40 patients following GKR. Nine out of 53 surveyed patients (17%) had normal IGF-I and GH nadir below 2.6 mIU/l at glucose tolerance tests, while not on hormone-suppressive medication. Two patients developed minor visual field defects. Eight patients started hormone substitution therapy during the follow-up period.
Conclusion:
GKR is an effective adjuvant treatment for residual acromegaly, carrying few side effects.
